HOSPITALS
CES
2022 : Abbott Keynote
With these treatments , Abbott is ensuring that they are part of the advancement of patient care , which includes diversity in clinical trials .
“ I put it in this perspective : the work of global clinical affairs , which I lead in this organisation , is to evaluate the new therapies that we think could be helpful for patients suffering from vascular disease ,” said Jones-McMeans . “ Doing that , we must develop clinical trials that lead to the advancement of medicine . However , what has happened traditionally is that the patients in clinical trials have not always been representative of the total population .”
For clinical trials throughout history – be it academia or large companies – people of colour and women make up
“ THE BARBERSHOP HYPERTENSION STUDY WAS ABLE TO REACH OUT TO THE COMMUNITY THROUGH BARBERSHOPS ”
JENNIFER JONES-MCMEANSE DIVISIONAL VICE PRESIDENT OF GLOBAL CLINICAL AFFAIRS , ABBOTT a smaller proportion . “ While we know that the therapies are safe and that they work , we ' re not able to look at the patient – the female patient , the African American , the Latino patient – and say , ‘ Yes , your population was part of these trials , and so we have even more confidence that they work in your population ’. We need to be able to do that .”
In the United States , the Food and Drug Administration ( FDA ) put out guidance encouraging researchers to ensure that people of colour and women are wellrepresented in their trials .
“ They understand we do need to have the data that supports the notion that not only is this device safe and works , but it ' s safe and works across all populations ,” said Jones-McMeans .
46 September 2022